A Phase II Trial of CD24Fc for Prevention of Acute Graft-versus-Host Disease Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplant

Trial Profile

A Phase II Trial of CD24Fc for Prevention of Acute Graft-versus-Host Disease Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplant

Recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Jul 2017

At a glance

  • Drugs CD24Fc (Primary) ; Methotrexate; Tacrolimus
  • Indications Graft-versus-host disease
  • Focus Therapeutic Use
  • Sponsors OncoImmune
  • Most Recent Events

    • 12 Jan 2017 According to OncoImmune media release, CD24Fc has received orphan drug designation for GvHD in both the US and Europe.
    • 30 Aug 2016 Status changed from not yet recruiting to recruiting.
    • 05 Jul 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top